In Silico and In Vitro Experimental Studies of New Dibenz[<i<b</i<,<i<e</i<]oxepin-11(6<i<H</i<)one O-(arylcarbamoyl)-oximes Designed as Potential Antimicrobial Agents
In a drug-repurposing-driven approach for speeding up the development of novel antimicrobial agents, this paper presents for the first time in the scientific literature the synthesis, physico-chemical characterization, in silico analysis, antimicrobial activity against bacterial and fungal strains in planktonic and biofilm growth state, as well as the in vitro cytotoxicity of some new 6,11-dihydrodibenz[<i<b</i<,<i<e</i<]oxepin-11(6<i<H</i<)one O-(arylcarbamoyl)oximes. The structures of intermediary and final substances (compounds <b<7a</b<−<b<j</b<) were confirmed by <sup<1</sup<H-NMR, <sup<13</sup<C-NMR and IR spectra, as well as by elemental analysis. The in silico bioinformatic and cheminformatic studies evidenced an optimal pharmacokinetic profile for the synthesized compounds <b<7a</b<−<b<j</b<, characterized by an average lipophilic character predicting good cell membrane permeability and intestinal absorption; low maximum tolerated dose for humans; potassium channels encoded by the hERG I and II genes as potential targets and no carcinogenic effects. The obtained compounds exhibited a higher antimicrobial activity against the planktonic Gram-positive <i<Staphylococcus aureus</i< and <i<Bacillus subtilis</i< strains and the <i<Candida albicans</i< fungal strain. The obtained compounds also inhibited the ability of <i<S. aureus</i<, <i<B. subtilis</i<, <i<Escherichia coli</i< and <i<C. albicans</i< strains to colonize the inert substratum, accounting for their possible use as antibiofilm agents. All the active compounds exhibited low or acceptable cytotoxicity levels on the HCT8 cells, ensuring the potential use of these compounds for the development of new antimicrobial drugs with minimal side effects on the human cells and tissues..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:25 |
|---|---|
| Enthalten in: |
Molecules - 25(2020), 2, p 321 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ilinca Margareta Vlad [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| Themen: |
Antibacterial |
|---|
| doi: |
10.3390/molecules25020321 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ047759232 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ047759232 | ||
| 003 | DE-627 | ||
| 005 | 20230308130051.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230227s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/molecules25020321 |2 doi | |
| 035 | |a (DE-627)DOAJ047759232 | ||
| 035 | |a (DE-599)DOAJ320640d2e3c24adfbcd47e7d7f47b473 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 050 | 0 | |a QD241-441 | |
| 100 | 0 | |a Ilinca Margareta Vlad |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a In Silico and In Vitro Experimental Studies of New Dibenz[<i<b</i<,<i<e</i<]oxepin-11(6<i<H</i<)one O-(arylcarbamoyl)-oximes Designed as Potential Antimicrobial Agents |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a In a drug-repurposing-driven approach for speeding up the development of novel antimicrobial agents, this paper presents for the first time in the scientific literature the synthesis, physico-chemical characterization, in silico analysis, antimicrobial activity against bacterial and fungal strains in planktonic and biofilm growth state, as well as the in vitro cytotoxicity of some new 6,11-dihydrodibenz[<i<b</i<,<i<e</i<]oxepin-11(6<i<H</i<)one O-(arylcarbamoyl)oximes. The structures of intermediary and final substances (compounds <b<7a</b<−<b<j</b<) were confirmed by <sup<1</sup<H-NMR, <sup<13</sup<C-NMR and IR spectra, as well as by elemental analysis. The in silico bioinformatic and cheminformatic studies evidenced an optimal pharmacokinetic profile for the synthesized compounds <b<7a</b<−<b<j</b<, characterized by an average lipophilic character predicting good cell membrane permeability and intestinal absorption; low maximum tolerated dose for humans; potassium channels encoded by the hERG I and II genes as potential targets and no carcinogenic effects. The obtained compounds exhibited a higher antimicrobial activity against the planktonic Gram-positive <i<Staphylococcus aureus</i< and <i<Bacillus subtilis</i< strains and the <i<Candida albicans</i< fungal strain. The obtained compounds also inhibited the ability of <i<S. aureus</i<, <i<B. subtilis</i<, <i<Escherichia coli</i< and <i<C. albicans</i< strains to colonize the inert substratum, accounting for their possible use as antibiofilm agents. All the active compounds exhibited low or acceptable cytotoxicity levels on the HCT8 cells, ensuring the potential use of these compounds for the development of new antimicrobial drugs with minimal side effects on the human cells and tissues. | ||
| 650 | 4 | |a dibenz[<i<b</i<,<i<e</i<]oxepins | |
| 650 | 4 | |a oxime carbamates | |
| 650 | 4 | |a antibacterial | |
| 650 | 4 | |a antifungal | |
| 650 | 4 | |a antibiofilm | |
| 650 | 4 | |a in silico | |
| 650 | 4 | |a in vitro cytotoxicity | |
| 653 | 0 | |a Organic chemistry | |
| 700 | 0 | |a Diana Camelia Nuta |e verfasserin |4 aut | |
| 700 | 0 | |a Cornel Chirita |e verfasserin |4 aut | |
| 700 | 0 | |a Miron Teodor Caproiu |e verfasserin |4 aut | |
| 700 | 0 | |a Constantin Draghici |e verfasserin |4 aut | |
| 700 | 0 | |a Florea Dumitrascu |e verfasserin |4 aut | |
| 700 | 0 | |a Coralia Bleotu |e verfasserin |4 aut | |
| 700 | 0 | |a Speranța Avram |e verfasserin |4 aut | |
| 700 | 0 | |a Ana Maria Udrea |e verfasserin |4 aut | |
| 700 | 0 | |a Alexandru Vasile Missir |e verfasserin |4 aut | |
| 700 | 0 | |a Luminita Gabriela Marutescu |e verfasserin |4 aut | |
| 700 | 0 | |a Carmen Limban |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Molecules |d MDPI AG, 2003 |g 25(2020), 2, p 321 |w (DE-627)DOAJ000105902 |x 14203049 |7 nnns |
| 773 | 1 | 8 | |g volume:25 |g year:2020 |g number:2, p 321 |
| 856 | 4 | 0 | |u https://doi.org/10.3390/molecules25020321 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/320640d2e3c24adfbcd47e7d7f47b473 |z kostenfrei |
| 856 | 4 | 0 | |u https://www.mdpi.com/1420-3049/25/2/321 |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/1420-3049 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |d 25 |j 2020 |e 2, p 321 | ||